Company intelligence / Profile preview

TMRC

Shinjuku-ku, Tokyo Metropolis, Japan

Ownership: Private
Employees: ~11
Development stage: Other

Overview

TMRC’s lead program, tamibarotene (TM-411), reached Phase 3 in partnership with Syros Pharmaceuticals for HR-MDS patients overexpressing RARA, but did not meet the primary endpoint. The partnership was terminated in April 2025, with global rights reverting to TMRC. Clinical studies have included acute promyelocytic leukemia, hepatocellular carcinoma, and pediatric indications. TMRC continues to consider next steps based on existing data[3].

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Syros Pharmaceuticals (licensee, terminated 2025)Ohara Pharmaceutical (licensee, pediatric cancer, Japan)Choongwae Pharma Corporation (licensee, South Korea, APL)Oder-Made Souyaku (licensee, China, APL)Children's Hospital Los Angeles (collaboration in neutropenia)

Beyond the preview

Go deeper on TMRC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMRC.

Explore the full profile